Palabras clave
seguridad del paciente
uso racional de medicamentos
revisión de la medicación
farmacéutico clínico
Resumen
La idoneidad de la prescripción constituye una estrategia fundamental para fortalecer la seguridad del paciente y promover el uso racional de los medicamentos. El objetivo de esta revisión narrativa fue analizar la evidencia científica disponible sobre sus principales componentes, las herramientas para su evaluación, sus implicaciones para la seguridad del paciente y el papel del farmacéutico clínico. Se realizó una búsqueda en PubMed, SciELO, Google Scholar y documentos de organismos internacionales. La evidencia revisada muestra que la evaluación sistemática de la prescripción permite prevenir problemas relacionados con la farmacoterapia, optimizar los tratamientos y disminuir eventos adversos. En México, fortalecer su implementación representa una oportunidad para mejorar la calidad de la atención y la seguridad del paciente.
Referencias
1. Persaud N, Workentin A, Rizvi A, Pierson T, Bortolussi- Courval E, Liu K, et al. Interventions to address potentially inappropriate prescribing for older primary care patients: a systematic review and meta-analysis. JAMA Netw Open. 2025;8(6):e2517965. doi:10.1001/ jamanetworkopen.2025.17965
2. Liu Y, Miner TW, Zouaidi K, Roy AN, Walji MF, Ray KN, et al. Medication prescribing checklists and their impact on patient safety: a scoping review. J Am Pharm Assoc (2003). 2025;65(5):102472. doi:10.1016/j. japh.2025.102472
3. Kinahan C, Kirke C, O'Hagan L, Moriarty F, Murphy KD, Sahm LJ, et al. Evaluating the impact of general practice pharmacist-led person-centred medicines reviews on medicines appropriateness and patient- reported outcome measures. Br J Clin Pharmacol. 2025;91(6):1802-1820. doi:10.1111/bcp.16372
4. Kroon D, Vervloet M, van Dijk L, de Bruijne MC, van Weert HCPM. Effectiveness of interventions aiming to reduce inappropriate drug prescribing: an overview of interventions. J Pharm Health Serv Res. 2021;12(3):423-433. doi:10.1093/jphsr/rmab038
5. Fernandes L, McCarthy D, McCormack C, Leahy A, Harnett A, Mohamed A, et al. Evidence on interventions that target prescribing appropriateness in older adults attending the emergency department and other acute care settings: a scoping review. Int J Clin Pharm. 2026. doi:10.1007/s11096-026-02170-8
6. Zavaleta-Monestel E, Mora-Jiménez J, Herrera-Jiménez L, Chaves-Arroyo A, Cruz Mora K, Arguedas-Chacón S. Pharmacist-led deprescribing interventions in older adults: a systematic review of medication appropriateness, patient safety, and clinical outcomes. Cureus. 2026;18(4):e106525. doi:10.7759/ cureus.106525
7. Rodrigues DA, Plácido AI, Mateos-Campos R, Figueiras A, Herdeiro MT, Roque F. Effectiveness of interventions to reduce potentially inappropriate medication in older patients: a systematic review. Front Pharmacol. 2022;12:777655. doi:10.3389/fphar.2021.777655
8. Bian J, Li Q, Li J, Yang N, Zhang W, Mei D, et al. Guideline for the evaluation of prescription appropriateness. Ann Transl Med. 2021;9(16):1352. doi:10.21037/atm- 20-7502
9. Hall RK, Kazancıoğlu R, Thanachayanont T, Wong G, Sabanayagam D, Battistella M, et al. Drug stewardship in chronic kidney disease to achieve effective and safe medication use. Nat Rev Nephrol. 2024;20(6):386- 401. doi:10.1038/s41581-024-00823-3
10. Wilson JA, Ratajczak N, Halliday K, Battistella M, Naylor H, Sheffield M, et al. Medications for community pharmacists to dose adjust or avoid to enhance prescribing safety in individuals with advanced chronic kidney disease: a scoping review and modified Delphi. BMC Nephrol. 2024;25(1):386. doi:10.1186/s12882- 024-03829-y
11. Anlay DZ, Paque K, Van Leeuwen E, Cohen J, Dilles T. Tools and guidelines to assess the appropriateness of medication and aid deprescribing: an umbrella review. Br J Clin Pharmacol. 2024;90(1):12-106. doi:10.1111/ bcp.15906
12. Hanlon JT, Schmader KE. The Medication Appropriateness Index: a clinimetric measure. Psychother Psychosom. 2022;91(2):78-83. doi:10.1159/000521699
13. O'Mahony D, Cherubini A, Renom Guiteras A, Denkinger M, Beuscart JB, Onder G, et al. STOPP/ START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023- 00777-y
14. The 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/ jgs.18372
15. Lisowska A, Czepielewska E, Rydz M, Dworakowska A, Makarewicz-Wujec M, Kozłowska-Wojciechowska M. Applicability of tools to identify potentially inappropriate prescribing in elderly during medication review: comparison of STOPP/START version 2, Beers 2019, EU(7)-PIM list, PRISCUS list, and Amsterdam tool—a pilot study. PLoS One. 2022;17(9):e0275456. doi:10.1371/journal.pone.0275456
16. Zhu X, Zhang F, Zhao Y, Zhang W, Zhang Y, Wang J. Evaluation of potentially inappropriate medications for the elderly according to Beers, STOPP, START, and Chinese criteria. Front Pharmacol. 2024;14:1265463. doi:10.3389/fphar.2023.1265463
17. Xu Z, Liang X, Zhu Y, Lu Y, Ye Y, Fang L, et al. Factors associated with potentially inappropriate prescriptions and barriers to medicines optimisation among older adults in primary care settings: a systematic review. Fam Med Community Health. 2021;9(4):e001325. doi:10.1136/fmch-2021-001325
18. Lampe D, Grosser J, Gensorowsky D, Witte J, Muth C, van den Akker M, et al. The relationship of continuity of care, polypharmacy and medication appropriateness: a systematic review of observational studies. Drugs Aging. 2023;40(6):473-497. doi:10.1007/s40266-023- 01022-8
19. Clark CM, Eimer MC, Intorre FM. Transitions of care: strategies for medication optimization and deprescribing in older adults. J Gerontol Nurs. 2023;49(12):5-10. doi:10.3928/00989134-20231107- 02
20. Hung A, Kim YH, Pavon JM. Deprescribing in older adults with polypharmacy. BMJ. 2024;385:e074892. doi:10.1136/bmj-2023-074892
21. Schiavo G, Forgerini M, Lucchetta RC, Silva GO, Mastroianni PDC. Cost of adverse drug events related to potentially inappropriate medication use: a systematic review. J Am Pharm Assoc (2003). 2022;62(5):1463-1476.e14. doi:10.1016/j. japh.2022.04.008
22. Secretaría de Salud. Norma Oficial Mexicana NOM- 220-SSA1-2016, Instalación y operación de la farmacovigilancia [Internet]. México: Diario Oficial de la Federación; 2017 [citado el 3 septiembre 2026]. Disponible en: https://dof.gob.mx/nota_detalle. php?codigo=5490830&fecha=19/07/2017
23. Haerdtlein A, Debold E, Rottenkolber M, Boehmer AM, Pudritz YM, Shahid F, et al. Which adverse events and which drugs are implicated in drug-related hospital admissions? A systematic review and meta-analysis. J Clin Med. 2023;12(4):1320. doi:10.3390/jcm12041320
24. Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4150-4172. doi:10.1111/bcp.14870
25. Inglis JM, Caughey G, Thynne T, Brotherton K, Liew D, Mangoni AA, et al. Inappropriate prescribing and association with readmission or mortality in hospitalised older adults with frailty: a systematic review and meta-analysis. BMC Geriatr. 2024;24:718. doi:10.1186/s12877-024-05297-3
26. Durand M, Castelli C, Roux-Marson C, Kinowski JM, Leguelinel-Blache G. Evaluating the costs of adverse drug events in hospitalized patients: a systematic review. Health Econ Rev. 2024;14:11. doi:10.1186/ s13561-024-00481-y /index.php/revistaconamed/index
27. World Health Organization. Global burden of preventable medication-related harm in health care: a systematic review [Internet]. Geneva: World Health Organization; 2024 [citado el 15 julio 2026]. Disponible en: https://www.who.int/publications/i/ item/9789240088887
28. Costello J, Barras M, Foot H, Cottrell N. The impact of hospital-based post-discharge pharmacist medication review on patient clinical outcomes: a systematic review. Explor Res Clin Soc Pharm. 2023;11:100305. doi:10.1016/j.rcsop.2023.100305
29. Ciudad-Gutiérrez P, del Valle-Moreno P, Lora- Escobar SJ, Guisado-Gil AB, Alfaro-Lara ER. Electronic medication reconciliation tools aimed at healthcare professionals to support medication reconciliation: a systematic review. J Med Syst. 2024;48(1):2. doi:10.1007/s10916-023-02008-0
30. Studer H, Imfeld-Isenegger TL, Beeler PE, Ceppi MG, Rosen C, Bodmer M, et al. The impact of pharmacist- led medication reconciliation and interprofessional ward rounds on drug-related problems at hospital discharge. Int J Clin Pharm. 2023;45(1):117-125. doi:10.1007/s11096-022-01496-3
31. Zaij S, Lemaire A, Bosson JL, François P, Bedouch P. Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review. BMC Health Serv Res. 2023;23:874. doi:10.1186/s12913-023-09512-6
32. Leyva-López Y, Torres-Peláez ML, Guerrero-Barrera A, Padilla-Flores I. Validación de la idoneidad de la prescripción médica en pacientes cardiópatas. Arch Cardiol Mex. 2022;92(1):75-84. doi:10.24875/ ACM.20000418
33. Vargas López LC, Viso Gurovich F, Dreser Mansilla A, Wirtz VJ, Reich MR. The implementation of pharmaceutical services in public hospitals in Mexico: an analysis of the legal framework and organizational practice. J Pharm Policy Pract. 2021;14(1):41. doi:10.1186/s40545-021-00318-7
34. Vargas López LC, Wirtz VJ, Reich MR. Pharmaceutical services in public hospitals in Mexico: a cross- sectional study. Int J Pharm Pract. 2022;30(2):143-152. doi:10.1093/ijpp/riac015
35. Consejo de Salubridad General. Modelo Único de Evaluación de la Calidad [Internet]. México: Gobierno de México; 2024 [citado el 10 agosto 2026]. Disponible en: https://www.gob.mx/csg/acciones-y-programas/ modelo-unico-de-evaluacion-de-la-calidad
36. Farmacopea de los Estados Unidos Mexicanos. Suplemento para establecimientos dedicados a la venta y suministro de medicamentos, dispositivos médicos y demás insumos para la salud 7.0. México: Comisión Permanente de la Farmacopea de los Estados Unidos Mexicanos; 2025
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.